Embecta Corp. (EMBC) stock
EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 15/3079% below fair value
$6.43−0.10 (-1.53%)
Close on Nov 12, 2026Market cap $364.32MP/E 4.4Yield 9.33%
Embecta EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Embecta's EPS for the twelve months ending Jun 30, 2026 was $1.47, up 2.8% year over year. For fiscal 2025 it was $1.62, up 20.9% from the year before. The highest annual figure on record is $7.50 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.62 | +20.9% |
| FY2024 | Sep 30, 2024 | $1.34 | +9.8% |
| FY2023 | Sep 30, 2023 | $1.22 | -68.6% |
| FY2022 | Sep 30, 2022 | $3.89 | -46.6% |
| FY2021 | Sep 30, 2021 | $7.28 | -2.9% |
| FY2020 | Sep 30, 2020 | $7.50 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $0.36 | -53.8% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$0.07 | -117.5% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $0.74 | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $0.44 | +76.0% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $0.78 | +212.0% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $0.40 | -20.0% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $0.00 | -100.0% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $0.25 | +150.0% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $0.25 | -3.8% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $0.50 | +108.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $0.35 | -42.6% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $0.10 | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $0.26 | -75.7% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $0.24 | -82.6% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $0.61 | -64.7% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$0.31 | -117.5% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $1.07 | -40.9% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $1.38 | -26.2% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $1.73 | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $1.77 | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $1.81 | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $1.87 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?